Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy

Clinical Infectious Diseases

Volumn 53, Issue 5, 2011, Pages 490-496

  Mehta, Sapna A ^a   Ahmed, Aabid ^b   Laverty, Maura ^a   Holzman, Robert S ^a   Valentine, Fred ^a   Sivapalasingam, Sumathi ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Bomu Medical Centre   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACHILLES REFLEX; ADULT; ANEMIA; ARTICLE; BODY MASS; CD4+ T LYMPHOCYTE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TUBERCULOSIS; VIBRATION SENSE;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KENYA; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 80052002207     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir432     Document Type: Article

References (27)

1. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12:753-60. (Pubitemid 47235489)
2. Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007; 44:456-62. (Pubitemid 46555382)
3. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr 2007; 45:304-10. (Pubitemid 47012377)
4. Hoffmann CJ, Fielding KL, Charalambous S, et al. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS 2008; 22:67-74. (Pubitemid 350294879)
5. Millogo A, Lankoande D, Yameogo I, Yameogo AA, Sawadogo AB. Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso [in French]. Bull Soc Pathol Exot 2008; 101:11-3.
6. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005; 10:464-70. (Pubitemid 40712431)
7. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40:336-43. (Pubitemid 41533075)
8. Ferrari S, Vento S, Monaco S, et al. Human immunodeficiency virusassociated peripheral neuropathies. Mayo Clin Proc 2006; 81:213-9. (Pubitemid 43205776)
9. Njoroge J, Reidy W, John-Stewart G, Attwa M, et al. Incidence of peripheral neuropathy among patients receiving HAART regimens containing stavudine vs. zidovudine in Kenya. In Abstracts of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa: IAS, 2009.
10. Sacktor N, Nakasujja N, Skolasky RL, et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009; 72:165-70.
11. van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Att E, Reid T. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg 2010; 104:148-53.
12. Cherry CL, Wesselingh SL, Lal L, McArthur JC. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 2005; 65:1778-81.
13. Mehta SA, Ahmed A, Kariuki BW, et al. Implementation of a validated peripheral neuropathy screening tool in patients receiving anti-retroviral therapy in Mombasa, Kenya. Am J Trop Med Hyg 2010; 83:565-70.
14. WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children. Available at: http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf. Accessed 25 April 2010.
15. Peduzzi P, Guo Z, Marottoli RA, Gill TM, Araujo K, Allore HG. Improved self-confidence was a mechanism of action in two geriatric trials evaluating physical interventions. J Clin Epidemiol 2007; 60:94-102. (Pubitemid 44856240)
16. Guarino P, Lamping DL, Elbourne D, Carpenter J, Peduzzi P. A brief measure of perceived understanding of informed consent in a clinical trial was validated. J Clin Epidemiol 2006; 59:608-14.
17. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48:1503-10. (Pubitemid 26035533)
18. Nakamoto B, McMurtray A, Davis J, et al. Incident neuropathy in HIV-infected patients on HAART. AIDS Res Hum Retroviruses 2010; 26:759-65.
19. Ellis R, Rosario D, Clifford D, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010; 67:552-8.
20. Simpson DM, Kitch D, Evans SR, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006; 66:1679-87. (Pubitemid 43964622)
21. Cherry CL, Affandi JS, Imran D, et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology 2009; 73:315-20.
22. Currier JS, Spino C, Grimes J, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000; 24:316-24.
23. Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996; 101:34-40. (Pubitemid 26285938)
24. Kempf MC, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr 2009; 52:336-41.
25. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to anti-retroviral drugs. Top HIV Med 2003; 11:55-9.
26. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Available at: http://whqlibdoc. who.int/publications/2010/9789241599764-eng.pdf. Accessed 31 August 2010.
27. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005; 40:148-57. (Pubitemid 40053473)